Observational study of Sorba View 2000, Sorba View' Ultimate and Secure View Port AFZ dressings used on Central Venous Catheters in 11 Italian Oncology, Hematology and Pain Cehters.
: ECOG scale of skin toxicity (Rasero, 2000) Grade Symptom or Visual Indicator Note: During the planning phase ofthe study the group explained the rej~rences ofthe Grades in further detail: Grade 0 means healthy intact skin without signs ofphlogosis; Grade I means the presence ofh~eremia greater than 1 centimeter at the exit point ofthe 0/C +1-fibrin; Grade 2 means greater than I and less than 2 centimeters at the point ofexit ofthe CVC +1-fibrin; Grade 3 means h~eremia, secretion, pus, +1-fibrin. Grade 4 was not defined as it had been established that the patient would have already abandoned the study with grade 2 or 3.
Background:
C entral venous catheters (CVCs) are extremely important devices in the management of patients who must undergo chemotherapy treatment (Oncology Nursing Society (ONS), 2004), bone marrow transplant, parenteral nutrition, transfusions and analgesic therapies (Centers for Disease Control (CDC), 2000) . The use of these three types of CVCs has increased considerably over recent years in order to reduce the incidence of extravasations and to preserve the venous characteristics of the patient. At the same time, the increase in the use of CVCs creates new problems including the prevention of possible infections. In immunodeficient patients, the nurse must pay particular attention to skin hygiene (Larson, 2001 ) and use and adopt suitable behaviour to lower the microbial load. Consequently, ever-increasing competencies are required of nurses who manage the dressing care of CVCs Hoffman, Weber, Samsa,and Rutala, 1992; Shivan, et al., 1991; Woods, Nass, and Deisch, 2000) . In consideration of our desire to meet and comply with the Atlanta 2002 CDC Guidelines (O'Grady, et al., 2002) an Italian multi-center observational study was planned using new, advanced feature CVC dressings recently introduced in Italy: SecureView Port AFZ, a specialized implanted port dressing with a small adhesive free zone over the noncoring needle area; SorbaView Ultimate high MVTR dressing; and standard SorbaView 2000 dressing. The dressings are manufactured under the Centurion brand by Tn-State Ho spital Supply Corp., Howell, MI, USA. SecureView Port AFZ dressings were selected for use over noncoring needles inserted cutaneously into implanted infusion ports on 293 patients. Two different dressing sizes were used. Two different geometric sizes and shapes of SorbaView Ultimate dressings were used at jugular and P1CC sites on 27 patients. Three sizes of SorbaView 2000, appropriate in shape for anatomical insertion site and type size configuration of vascular access catheter being used, were applied to 115 patients. These seven code numbers from three families of SorbaView dressings were selected as being able to accommodate all foreseen vascular access device's (VAD's) clinical situations for all patients, all anatomical insertion sites, and all VAD configurations (size, shape, lumen count, safety noncoring needle superstructure, pigtails, etc). Dressings were selected appropriately to fit the clinical situation.
Nursing teams from 11 oncology and hematology centers for adults in central and northern Italy participated in the study. Each center had a designated study coordinator.
Objectives
• Examine the comfort of patients resulting from the SorbaView and SecureView dressings.
• Evaluate the incidence of infections.
• Monitor the average duration of dwell time of the dressings.
Methods, Materials, Conditions 1. Patients, Consent, Enrollment, Skin Lesion Exclusion, ECOG (Eastern Cooperative Oncology Group) Scale of Skin Toxicity, Study Size All patients were informed verbally by study center profes sional nurses of the intent to use SorbaView and/or SecureView dressings on them as part of a dressing study; patients gave their verbal consent to the use of the new dressings. (Note: pro fessional nurses in Italy are authorized by their directors/chief physicians of their operational units to obtain patient verbal consentfor study purposes.)
Inclusion criteria: Carriers of totally or partially implantable CVCs, without active skin lesions at the site of insertion, subject ed to autotransplant of staminal cells and high-dose chemothera py, pain therapy, radio and chemotherapy, and plasmapheresis.
Exclusion criteria: Documented infection at the site of in sertion with major skin lesion (Grade 2 3 according to the ECOG scale of skin toxicity Discussion and Conclusion Data obtained from this observational study makes it pos sible to draw several objective conclusions regarding the dress ings used in this study, as well as some logically following sub jective inferences.
In the first place, dressing dwell time is satisfactory and com pliant with Atlanta CDC Guidelines. No minimum dwell times for dressings are set in these guidelines. Obviously, the longer dwell time that is free of troubles, the better it is for patient, nurse, hospital, economics, and health care system generally.
The good dressing dwell time is also associated with a high degree of dressing adhesion, as the total number of dressings that became detached (0.57%) or partially detached (6.75%) is small. Further, the partially detached dressings were not suf ficiently loose to justify an unscheduled dressing change, as catheter security and contamination barriers were still intact. It is important to note that no other ancillary securement devices, such as stand alone anchors or tapes, were used under or on the dressing, near it, or on the patient as supplementary cath eter holding; merely the two dressing parts included in each individual, sterile unit dressing package were used in studied patients. This study shows, by not having them present, that such costly additional measures are not needed to achieve long dressing dwell times.
Regarding the safety profile, the objective reporting of the skin conditions observed at the dressing showed a slight ten dency to the development of major lesions. These observations were limited to hematology patients in cases that allow a cer tain degree of prognosis for this complication.
Only 4.83% of patients had to abandon the study due to criticality. However, several of these patients were subjected to treatment with MOAB (monoclonal anti-EGFR antibod ies), and therefore subject to dermatologic toxicity unrelated to dressings as a cause, especially in view of the long dress ing dwell times achieved. Others, affected by hematological neoplasias, and therefore subject to prolonged and severe neu tropenias, have a high risk of infection regardless of the dress ing's presence or not, or the timing and interval of the dressing changes (Rasero, et al., 2000) .
From the subjective viewpoint a large number of patients (84%) were satisfied with the functionality of the dressings studied. Thirty-two patients were enrolled by the Centre of Analgesic Therapy in Genova. Of these, 23 patients who carried epidural catheters were able to maintain the epidural catheter; and the absorbent pad of the dressing in place made it possible to keep the point of insertion dry and sterile.
The results of this observational study for long dressing dwell time, high dressing adhesion with a very low level of skin issues, in this susceptible patient population of oncology (Zitella, et al., 2006) and hematology, enable us to sustain a good profile of effi cacy, tolerability and safety and to make some logical inferences and conclusions on the following clinical parameters:
• Visibility of the site of insertion • Decrease of admittances to day hospital and/or sterile rooms (longer dressing dwell times means patient does not have to come back to hospital for dressing change as frequently) • Optimization of nursing time (International Nurse Counsel, 2006 ) (greater number of days of dwell time of the dressing means fewer dressing changes and less labor) • Decrease in dressing and dressing change material costs (use of fewer dressings due to longer dwell times; dress ings, dressing change trays and other materials needed are directly related to dressing dwell time) • Decrease in the risk of contamination of the insertion site (greater number of days of dwell time of dressing; every time a dressing is changed, the entire insertion site wound and catheter lumen is exposed to potential contamination in creasing the infection potential for what is already the most compromised group of VAD/dressing patients) Note: No quantitative data was collected on the above four parameters. It is merely authors' logical deductions.
Further comparative studies with other devices could be useful in the future in order to improve the management of these delicate, most susceptible patients. Using new products and technologies to optimize the competencies and techniques of colleagues on the basis of evidence based nursing (EBN) makes it possible to tackle difficult and intractable daily prob lems in the management of onco-hematological patients.
proliferation. An external top layer of non-woven fabric adds body to the film, prevents film from wrinkling and sticking to itself during application, creates a central site viewing window, and is comfortable to touch and wear for the patient. The dress ing can be positioned with only one hand and has a dwell time that can reach up to seven days (Lee, 2002 For the purpose of this study, CVCs have been divided into two different categories:
• Totally implantable port CVCs, on which was used Se cureView Port AFZ transparent fabric border dressings with a small non-adherent zone centered in the gas perme able transparent polyurethane window (SCVP44XT and SCVP66XT).
• Tunneled and non-tunneled CVCs (short-term, Hohn, with high flow for apheresis, supraclavicular Becton Dickinson SecalonTM, C.R. Bard Groshong , Epidural) on which was used SorbaView 2000 and SorbaView Ultimate gas permeable transparent window dressings with absorbent pad and fabric border (SV3ONXT, SV4OXT, SV44UXT). Epidural catheters for analgetic therapy, on which was used SorbaView 2000 gas permeable transparent window dressings with absorbent pad and fabric border (SV4OXT, SV48VXT).
Only one type of skin antiseptic cleaning agent was used PVP Povidone Iodine. No liquid skin protectant barriers were used. A liquid skin barrier can greatly weaken the adhesion of any dressing by substituting itself for the dressing's adhesive and interposing itself between the skin and the dressing's adhesive. The SorbaView dressing line is known to have a history of use in the USA with very few skin issues (Lee, 2002; Penney-Tim mons, 2005; Trotter, Brock, Schwaner, Conaway, and Bums, 2008; Winfield, Davis, Schwaner, Conaway, and Bums, 2007; Garcia, Jendresky, Landesman, Maher, and Nicolas, 2003) .
Operators
Nurses at each center were trained in the correct technique of dressing application and removal before enrollment of the patients:
• Interval times between two dressing changes was from 3 to 7/10 days depending on patient's course of therapy, end of therapy, and other variable situations.
• The number of dressings envisaged per patient for the study was three; however in some cases it was actually four or five dressings due to extended therapy, a particular type of therapy, or because some patients specifically requested that a SorbaView dressing continue to be used on them, despite three being attained.
• Familiarity with the ECOG scale of skin toxicity in detail (Table 1) 5. Data Collection The group produced three types of cards containing data col lection:
• • 94 were partially detached (6.75%), but did not justify chang ing dressing • Eight were detached (0.579') (Reason: difficult chemothera py or skin problems)
Of the 435 patients under observation, the condition of the skin at the point of insertion of the CVC or noncoring needle was noted according to the ECOG scale (Table 1 ). The observa tion was performed daily and the finding reported on the card, at the time of application and upon removal of the dressing, until the end of the study. Discussion and Conclusion Data obtained from this observational study makes it pos sible to draw several objective conclusions regarding the dress ings used in this study, as well as some logically following sub jective inferences.
• Visibility of the site of insertion • Decrease of admittances to day hospital and/or sterile rooms (longer dressing dwell times means patient does not have to come back to hospital for dressing change as frequently) • Optimization of nursing time (International Nurse Counsel, 2006 ) (greater number of days of dwell time of the dressing means fewer dressing changes and less labor) • Decrease in dressing and dressing change material costs (use of fewer dressings due to longer dwell times; dress ings, dressing change trays and other materials needed are directly related to dressing dwell time) • Decrease in the risk of contamination of the insertion site (greater number of days of dwell time of dressing; every time a dressing is changed, the entire insertion site wound and catheter lumen is exposed to potential contamination in creasing the infection potential for what is already the most compromised group of VAD/dres sing patients) Note: No quantitative data was collected on the above four parameters. It is merely authors' logical deductions.
